Abstract
non-l, 26% in naive patients and 0% in previously treated patients. In 2 patients HCV RNA negative at 12 months, treatment was continued. The following dose adjustments were required: 6/22 (27%) decrease in peg interferon (neutropenia n=2, clinical depression n=4), lo/22 (45%) decrease in ribavirin therapy due to anemia. Therapy was discontinued in 14/22 (63%) patients: 8/22 (36%) due to lack of response and 6/22 (27%) related to drug intolerance (i.e. rejection n=3, acute pancreatitis n=l, depression n=l, death n=l). Conclusion: Sustained virologic response using pegylated interferon a2b and ribavirin combination was observed in 20% of LT patients with HCV infection. The high rate of drug intolerance and lower response rates observed as compared to those in the immunocompetent population were limiting factors in the transplant setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
